Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59

Benzinga · 22h ago
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $64 to $59.